NR 565 Final Exam (2026)
Advanced Pharmacology Fundamentals
Complete Practice Questions 1-200 with Answers & Detailed
Rationales
Latest 2026/2027 Update | Chamberlain University (MSN-FNP)
SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS
(Questions 1-25)
QUESTION 1
A patient asks how a medication taken by mouth produces an effect in the body. The
APRN explains that the process by which a drug is absorbed, distributed, metabolized,
and excreted is known as:
A) Pharmacodynamics
B) Pharmacotherapeutics
C) Pharmacokinetics
D) Pharmacogenomics
CORRECT ANSWER: C) Pharmacokinetics
,RATIONALE: Pharmacokinetics is the study of drug movement throughout the body,
including absorption, distribution, metabolism, and excretion (ADME). Pharmacodynamics
is what the drug does to the body—the mechanism of action and effects.
Pharmacotherapeutics is the clinical application of drugs for treatment.
Pharmacogenomics studies how genetic variations affect drug response.
QUESTION 2
A drug that binds to a receptor and produces a response that is less than that of a full
agonist, even at maximal concentrations, is known as a:
A) Partial agonist
B) Inverse agonist
C) Competitive antagonist
D) Non-competitive antagonist
CORRECT ANSWER: A) Partial agonist
RATIONALE: A partial agonist has lower efficacy than a full agonist. It binds to and
activates a receptor but cannot produce a maximal response, even when all receptors are
occupied. An inverse agonist produces the opposite effect of an agonist. A competitive
antagonist binds to the receptor but produces no response, blocking the agonist from
binding.
QUESTION 3
An APRN is prescribing a medication that is known to be a CYP450 enzyme inducer.
What effect will this have on other medications metabolized by that enzyme pathway?
A) Increased serum levels of the other medications, potentially leading to toxicity
B) Decreased serum levels of the other medications, potentially leading to therapeutic
failure
,C) No effect on serum levels of the other medications
D) Prolonged half-life of the other medications
CORRECT ANSWER: B) Decreased serum levels of the other medications,
potentially leading to therapeutic failure
RATIONALE: CYP450 inducers increase liver enzyme activity, leading to faster breakdown
of medications metabolized through that pathway. This results in decreased serum
concentrations and potential therapeutic failure. Common inducers include rifampin,
phenytoin, carbamazepine, and St. John's Wort.
QUESTION 4
Which of the following is an example of a CYP450 inhibitor?
A) Rifampin
B) Phenytoin
C) Carbamazepine
D) Ketoconazole
CORRECT ANSWER: D) Ketoconazole
RATIONALE: Ketoconazole is a potent CYP450 inhibitor. Inhibitors decrease metabolic
activity, leading to increased serum concentrations of other medications metabolized by
that pathway. Mnemonic for inhibitors: "KICK" - Ketoconazole, Isoniazid, Cimetidine, and
Grapefruit juice. Rifampin, phenytoin, and carbamazepine are inducers.
QUESTION 5
, A medication with a narrow therapeutic index requires:
A) Less frequent monitoring
B) Close monitoring of serum drug levels
C) No special precautions
D) Higher doses for efficacy
CORRECT ANSWER: B) Close monitoring of serum drug levels
RATIONALE: Drugs with a narrow therapeutic index have a small margin between
therapeutic and toxic doses. Close monitoring is essential. Examples include digoxin,
lithium, warfarin, theophylline, and phenytoin. Serum drug level monitoring helps
maintain therapeutic effects while avoiding toxicity.
QUESTION 6
A 65-year-old male with cirrhosis is prescribed a medication that undergoes extensive
first-pass hepatic metabolism. The nurse practitioner understands that the bioavailability
of this medication will be significantly affected by which pharmacokinetic alteration?
A) Decreased absorption from the GI tract
B) Reduced first-pass metabolism leading to increased bioavailability
C) Enhanced renal elimination compensating for hepatic impairment
D) Increased protein binding reducing free drug concentration
CORRECT ANSWER: B) Reduced first-pass metabolism leading to increased
bioavailability
RATIONALE: In cirrhosis, first-pass hepatic metabolism is reduced due to damaged
hepatocytes and portosystemic shunting, leading to increased bioavailability of drugs that
normally undergo extensive first-pass metabolism. This requires dose reduction to avoid
toxicity.
Advanced Pharmacology Fundamentals
Complete Practice Questions 1-200 with Answers & Detailed
Rationales
Latest 2026/2027 Update | Chamberlain University (MSN-FNP)
SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS
(Questions 1-25)
QUESTION 1
A patient asks how a medication taken by mouth produces an effect in the body. The
APRN explains that the process by which a drug is absorbed, distributed, metabolized,
and excreted is known as:
A) Pharmacodynamics
B) Pharmacotherapeutics
C) Pharmacokinetics
D) Pharmacogenomics
CORRECT ANSWER: C) Pharmacokinetics
,RATIONALE: Pharmacokinetics is the study of drug movement throughout the body,
including absorption, distribution, metabolism, and excretion (ADME). Pharmacodynamics
is what the drug does to the body—the mechanism of action and effects.
Pharmacotherapeutics is the clinical application of drugs for treatment.
Pharmacogenomics studies how genetic variations affect drug response.
QUESTION 2
A drug that binds to a receptor and produces a response that is less than that of a full
agonist, even at maximal concentrations, is known as a:
A) Partial agonist
B) Inverse agonist
C) Competitive antagonist
D) Non-competitive antagonist
CORRECT ANSWER: A) Partial agonist
RATIONALE: A partial agonist has lower efficacy than a full agonist. It binds to and
activates a receptor but cannot produce a maximal response, even when all receptors are
occupied. An inverse agonist produces the opposite effect of an agonist. A competitive
antagonist binds to the receptor but produces no response, blocking the agonist from
binding.
QUESTION 3
An APRN is prescribing a medication that is known to be a CYP450 enzyme inducer.
What effect will this have on other medications metabolized by that enzyme pathway?
A) Increased serum levels of the other medications, potentially leading to toxicity
B) Decreased serum levels of the other medications, potentially leading to therapeutic
failure
,C) No effect on serum levels of the other medications
D) Prolonged half-life of the other medications
CORRECT ANSWER: B) Decreased serum levels of the other medications,
potentially leading to therapeutic failure
RATIONALE: CYP450 inducers increase liver enzyme activity, leading to faster breakdown
of medications metabolized through that pathway. This results in decreased serum
concentrations and potential therapeutic failure. Common inducers include rifampin,
phenytoin, carbamazepine, and St. John's Wort.
QUESTION 4
Which of the following is an example of a CYP450 inhibitor?
A) Rifampin
B) Phenytoin
C) Carbamazepine
D) Ketoconazole
CORRECT ANSWER: D) Ketoconazole
RATIONALE: Ketoconazole is a potent CYP450 inhibitor. Inhibitors decrease metabolic
activity, leading to increased serum concentrations of other medications metabolized by
that pathway. Mnemonic for inhibitors: "KICK" - Ketoconazole, Isoniazid, Cimetidine, and
Grapefruit juice. Rifampin, phenytoin, and carbamazepine are inducers.
QUESTION 5
, A medication with a narrow therapeutic index requires:
A) Less frequent monitoring
B) Close monitoring of serum drug levels
C) No special precautions
D) Higher doses for efficacy
CORRECT ANSWER: B) Close monitoring of serum drug levels
RATIONALE: Drugs with a narrow therapeutic index have a small margin between
therapeutic and toxic doses. Close monitoring is essential. Examples include digoxin,
lithium, warfarin, theophylline, and phenytoin. Serum drug level monitoring helps
maintain therapeutic effects while avoiding toxicity.
QUESTION 6
A 65-year-old male with cirrhosis is prescribed a medication that undergoes extensive
first-pass hepatic metabolism. The nurse practitioner understands that the bioavailability
of this medication will be significantly affected by which pharmacokinetic alteration?
A) Decreased absorption from the GI tract
B) Reduced first-pass metabolism leading to increased bioavailability
C) Enhanced renal elimination compensating for hepatic impairment
D) Increased protein binding reducing free drug concentration
CORRECT ANSWER: B) Reduced first-pass metabolism leading to increased
bioavailability
RATIONALE: In cirrhosis, first-pass hepatic metabolism is reduced due to damaged
hepatocytes and portosystemic shunting, leading to increased bioavailability of drugs that
normally undergo extensive first-pass metabolism. This requires dose reduction to avoid
toxicity.
